Honeywell International Inc. decreased its position in shares of Pfizer, Inc. (NYSE:PFE) by 83.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 225,000 shares of the biopharmaceutical company’s stock after selling 1,128,100 shares during the period. Honeywell International Inc.’s holdings in Pfizer were worth $7,697,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. E&G Advisors LP boosted its position in shares of Pfizer by 6.8% in the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 3,940 shares during the period. Prentiss Smith & Co. Inc. boosted its position in shares of Pfizer by 1.7% in the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 250 shares during the period. Carroll Financial Associates Inc. boosted its position in shares of Pfizer by 33.9% in the first quarter. Carroll Financial Associates Inc. now owns 197,820 shares of the biopharmaceutical company’s stock worth $6,767,000 after buying an additional 50,045 shares during the period. PagnatoKarp Partners LLC acquired a new position in shares of Pfizer during the fourth quarter worth $1,342,000. Finally, New England Research & Management Inc. boosted its position in shares of Pfizer by 0.5% in the first quarter. New England Research & Management Inc. now owns 59,651 shares of the biopharmaceutical company’s stock worth $2,041,000 after buying an additional 309 shares during the period. 69.94% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer, Inc. (NYSE:PFE) traded up 0.48% during mid-day trading on Friday, reaching $33.39. 14,393,883 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $33.25 and its 200 day moving average price is $33.42. The stock has a market capitalization of $198.58 billion, a PE ratio of 24.43 and a beta of 1.00. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.18.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.64 EPS. Equities research analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.83%. Pfizer’s payout ratio is 94.12%.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/26/honeywell-international-inc-sells-1128100-shares-of-pfizer-inc-pfe.html.

PFE has been the topic of a number of recent research reports. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets raised shares of Pfizer from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Barclays PLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $37.61.

In other news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,014 shares of company stock valued at $4,062,493. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.